Categories
Business

CureVac fails in pivotal COVID-19 vaccine trial – INQUIRER.net

German biotech CureVac NV said on Wednesday its COVID-19 vaccine was only 47% effective in a late-stage trial, missing the study’s main goal and throwing in …

  1. CureVac fails in pivotal COVID-19 vaccine trialINQUIRER.net
  2. 47% efficacy: Did Germany’s CureVac vaccine ultimately fail? | DW NewsDW News
  3. CureVac fails in pivotal COVID-19 vaccine trial with 47% efficacyINQUIRER.net
  4. Which Covid-19 vaccine is the best? That’s a complicated questionSouth China Morning Post
  5. Elon Musk-Backed CureVac Vaccine Flop Doesn’t Dent Promise of mRNABloomberg